|drug676||CVnCoV 12μg Wiki||0.50|
|drug1443||Hepatitis A vaccine Wiki||0.50|
|drug2593||Pneumococcal vaccine Wiki||0.50|
|D014777||Virus Diseases NIH||0.05|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There are 4 clinical trials
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
Description: by mean change in PaO2/FiO2 (PaO2=Partial pressure of oxygen; FiO2= Fraction of inspired oxygen)Measure: Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure Time: at end of 5 day treatment period
Description: demonstrated by bacterial or fungal cultureMeasure: incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection Time: during hospital admission (up to 28 days)
Description: defined by HS (Hemophagocytic Syndrome) scoreMeasure: number of patients developing features of secondary haemophagocytic lymphohistiocytosis Time: at enrolment, end of 5 day treatment period, 10 day period, 10-20 weeks
The coronavirus disease 2019 (COVID-19) has rapidly become a pandemic. COVID-19 poses a mortality risk of 3-7%, rising to 20% in older patients with co-morbidities. Of all infected patients, 15-20% will develop severe respiratory symptoms necessitating hospital admission. Around 5% of patients will require invasive mechanical ventilation, and up to 50% will die. Evidence in severe COVID-19 suggests that these patients experience cytokine storm and progressed rapidly with acute respiratory distress syndrome and eventual multi-organ failure. Early identification and immediate treatment of hyperinflammation is thus recommended to reduce mortality. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) has been shown to be a myelopoietic growth factor that has pleiotropic effects in promoting the differentiation of immature precursors into polymorphonuclear neutrophils, monocytes/ macrophages and dendritic cells, and also in controlling the function of fully mature myeloid cells. It plays an important role in priming monocytes for production of proinflammatory cytokines under TLR and NLR stimulation. It has a broad impact on the processes driving DC differentiation and affects DC effector function at the mature state. Importantly, GM-CSF plays a critical role in host defense and stimulating antiviral immunity. Detailed studies have also shown that GM-CSF is necessary for the maturation of alveolar macrophages from foetal monocytes and the maintenance of these cells in adulthood. The known toxicology, pharmacologic and safety data also support the use of Leukine® in hypoxic respiratory failure and ARDS due to COVID-19. This study aims to recruit patients with evidence of pneumonia and hypoxia who have increased risk for severe disease and need for mechanical ventilation. The overall hypothesis is that GM-CSF has antiviral immunity, can provide the stimulus to restore immune homeostasis in the lung with acute lung injury from COVID-19, and can promote lung repair mechanisms, which would lead to improvement in lung oxygenation parameters.
Description: To measure the effectiveness of Leukine® in restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation after 5 days of intravenous treatment through assessment of pre-treatment and post-treatment ratio of PaO2/FiO2, and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of inpatients.Measure: Measuring oxygenation Time: Day 1 to Day 6
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.
Description: The 8 point ordinal scale will be used, where 0 is not hospitalized, no clinical or virological evidence of infection, and 8 is death.Measure: Change in ordinal scale Time: 1-28 days
This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.
Description: Number of days to achieve at least 2-rank improvement on a 7-point ordinal scale from baseline until Day 28.Measure: 2-rank improvement on a 7-point ordinal scale Time: Period until Day 28 (including the case after discharge).
Description: Changes in alveolar-arterial oxygen partial pressure gradient (A-aDO) on Day 5 and Day 10 from baseline.Measure: Changes in alveolar-arterial oxygen partial pressure gradient (A-aDO) Time: Period until Day 28 (including the case after discharge).
Description: Number of days until discharge from baseline (days of shifting to Category 7 on a 7-point ordinal scale).Measure: Number of days until discharge from baseline Time: Period until Day 28 (including the case after discharge).
Description: Proportion of subjects whose category has shifted to Category 1 or 2 on a 7-point ordinal scale from baseline until Day 28Measure: Proportion of subjects whose category has shifted to Category 1 or 2 Time: Period until Day 28 (including the case after discharge).
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports